<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>ULCER DRUG WORKS IN TRIALS</title>
    <meta content="MB004743" name="slug"/>
    <meta content="13" name="publication_day_of_month"/>
    <meta content="9" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Wednesday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="6" name="print_page_number"/>
    <meta content="C" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Health; Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1230268"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="TECHNOLOGY BRIEFING: BIOTECHNOLOGY"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Repifermin (Drug)</classifier>
        <classifier class="indexing_service" type="descriptor">Tests and Testing</classifier>
        <classifier class="indexing_service" type="descriptor">Genetics and Heredity</classifier>
        <org class="indexing_service">Human Genome Sciences Inc</org>
        <person class="indexing_service">Pollack, Andrew</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Genetics and Heredity</classifier>
        <classifier class="online_producer" type="general_descriptor">Tests and Testing</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000913T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9C03E0D81438F930A2575AC0A9669C8B63" item-length="105" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>ULCER DRUG WORKS IN TRIALS</hl1>
      </hedline>
      <byline class="print_byline">By Andrew Pollack</byline>
      <byline class="normalized_byline">Pollack, Andrew</byline>
      <abstract>
        <p>Human Genome Sciences says repifermin, its drug for wound healing, has accelerated repair of chronic venous uclers in early Phase 2 clinical trial; repifermin is natural human protein and is believed to be first drug discovered using genomics that has shown effectiveness in radomized clinical trial (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>Human Genome Sciences said yesterday that its drug for wound healing had accelerated the repair of chronic venous ulcers in an early Phase 2 clinical trial. The drug, repifermin, is a natural human protein and is believed to be the first drug discovered using genomics that has shown effectiveness in a randomized clinical trial. In a test of 94 patients, 63 percent of patients who received the high dose and 71 percent who got the low dose achieved 75 percent wound closure after 12 weeks, compared with 45 percent of the patients who got a placebo.</p>
        <p>Andrew Pollack</p>
      </block>
      <block class="full_text">
        <p>Human Genome Sciences said yesterday that its drug for wound healing had accelerated the repair of chronic venous ulcers in an early Phase 2 clinical trial. The drug, repifermin, is a natural human protein and is believed to be the first drug discovered using genomics that has shown effectiveness in a randomized clinical trial. In a test of 94 patients, 63 percent of patients who received the high dose and 71 percent who got the low dose achieved 75 percent wound closure after 12 weeks, compared with 45 percent of the patients who got a placebo.</p>
        <p>Andrew Pollack</p>
        <p>TECHNOLOGY BRIEFING: BIOTECHNOLOGY</p>
      </block>
    </body.content>
  </body>
</nitf>
